Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
AC Immune SA
AC Immune SA
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme
The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Pfizer's haemophilia A/B therapeutic Hympavzi gains FDA approval
The pharma giant's once-weekly injectable can be administered subcutaneously and is able to significantly reduce annualised bleeding
Achieving sustainable oligonucleotide production at an industrial scale
Sustainability is becoming increasingly important in pharmaceutical manufacturing, so Bachem's Philipp Markolin shares some insight into planet-friendly peptide and...
The rise of small molecule enzyme substrates in microbiology
From bacterial detection to disease diagnostics, small molecule enzyme substrates are revolutionising the pharmaceutical industry
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
Collaboration will combine Alleo’s AI-based platform with Ubiquigent’s expertise in the DUB space to advance DUB-focused preclinical programmes
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
AC Immune strengthens management, appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
Pharmaceutical
AC Immune SA appoints Dr Marie Kosco-Vilbois
Neurodegenerative Disease company has new Chief Scientific Officer
Pharmaceutical
New strategic partnership focuses on Alzheimers
Swiss AC Immune and Chinese WuXi Biologics sign agreement
Research & Development
AC Immune and Lilly announce licence and collaboration agreement
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases
Pharmaceutical
Landmark for AC Immune Alzheimer and Down Syndrome vaccines
The swiss clinical stage biopharmaceutical company has a broad pipeline focused on neurodegenerative diseases
Subscribe now